Morris, Lynn
National Health Laboratory Service · University of the Witwatersrand · National Institute for Communicable Diseases
6 papers on CoChatORCID 0000-0003-3961-7828
Most cited papers
- Verified
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.
Abdool Karim, Q., Abdool Karim, S. S., Frohlich, J. A., Grobler, A. C., Baxter, C., Mansoor, L. E., Kharsany, A. B. M., Sibeko, S., Mlisana, K. P., Omar, Z., et al. (2010) · Science
HIV/AIDS Research and InterventionsHIV/AIDS drug development and treatment
Cited by 2,435
- Verified
SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma
Wibmer, C. K., Ayres, F., Hermanus, T., Madzivhandila, M., Kgagudi, P., Oosthuysen, B., Lambson, B. E., de Oliveira, T., Vermeulen, M., van der Berg, K., et al. (2021) · Nature Medicine
SARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections Studies
Cited by 1,147
- Verified
Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition
Corey, L., Gilbert, P. B., Juraska, M., Montefiori, D. C., Morris, L., Karuna, S. T., Edupuganti, S., Mgodi, N. M., deCamp, A. C., Rudnicki, E., et al. (2021) · New England Journal of Medicine
HIV Research and TreatmentHIV/AIDS Research and Interventions
Cited by 538
- Verified
High-Throughput Mapping of B Cell Receptor Sequences to Antigen Specificity
Setliff, I., Shiakolas, A. R., Pilewski, K. A., Murji, A. A., Mapengo, R. E., Janowska, K., Richardson, S., Oosthuysen, C., Raju, N., Ronsard, L., et al. (2019) · Cell
Monoclonal and Polyclonal Antibodies ResearchT-cell and B-cell Immunology
Cited by 314
- Verified
Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351)
Moyo-Gwete, T., Madzivhandila, M., Makhado, Z., Ayres, F., Mhlanga, D., Oosthuysen, B., Lambson, B. E., Kgagudi, P., Tegally, H., Iranzadeh, A., et al. (2021) · New England Journal of Medicine
SARS-CoV-2 and COVID-19 Researchvaccines and immunoinformatics approaches
Cited by 128
- Verified
Tenofovir 1% vaginal gel for prevention of HIV-1 infection in women in South Africa (FACTS-001): a phase 3, randomised, double-blind, placebo-controlled trial.
Delany-Moretlwe, S., Lombard, C., Baron, D., Bekker, L.-G., Nkala, B., Ahmed, K., Sebe, M., Brumskine, W., Nchabeleng, M., Palanee-Philips, T., et al. (2018) · The Lancet Infectious Diseases
HIV/AIDS Research and InterventionsHIV/AIDS drug development and treatment
Cited by 95
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free